Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL1508805 | 1.00 | LMNA (0.67) | LMNAMEN1KMT2ACA5ACA5B | |
| Tromethamine SCHEMBL5988271 | 1.00 | LMNA (0.67) | LMNAMEN1KMT2ACA5ACA5B | |
| Tromethamine SCHEMBL11143695 | 0.88 | MEN1 (0.59) | LMNAMEN1KMT2ACA5ACA5B | |
| Tromethamine SCHEMBL6064575 | 0.85 | LMNA (0.56) | LMNAMEN1KMT2ACA5ACA5B | |
| Tromethamine SCHEMBL21647312 | 0.83 | MEN1 (0.53) | LMNAMEN1KMT2ACA1CA2 | |
| Tromethamine SCHEMBL975 | 0.82 | — | — | |
| Tromethamine SCHEMBL3696191 | 0.82 | — | — | |
| Tromethamine SCHEMBL17484 | 0.82 | MEN1 (1.00) | LMNAMEN1KMT2AKDM4E | |
| Tromethamine SCHEMBL28672604 | 0.81 | MEN1 (0.50) | LMNAMEN1KMT2ACA1CA2 | |
| Tromethamine SCHEMBL5572478 | 0.79 | MEN1 (0.77) | LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480155-B2 | Nicking enzymes | LUMIRADX UK LTD. (GB) | 2025-11-25 | — | — | US | claimed |
| US-20220403459-A1 | IMPROVEMENTS IN OR RELATING TO NICKING ENZYMES | LUMIRADX UK LTD. (GB) | 2022-12-22 | — | — | US | claimed |
| EP-3987018-A1 | IMPROVEMENTS IN OR RELATING TO NICKING ENZYMES | LUMIRADX UK LTD (GB) | 2022-04-27 | — | — | EP | claimed |
| CN-113993995-A | Improvements in or relating to nicking enzymes | 卢米拉特英国有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-12480155-B2 | Nicking enzymes | LUMIRADX UK LTD. (GB) | 2025-11-25 | — | — | US | disclosed |
| US-20220403459-A1 | IMPROVEMENTS IN OR RELATING TO NICKING ENZYMES | LUMIRADX UK LTD. (GB) | 2022-12-22 | — | — | US | disclosed |
| EP-3987018-A1 | IMPROVEMENTS IN OR RELATING TO NICKING ENZYMES | LUMIRADX UK LTD (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993995-A | Improvements in or relating to nicking enzymes | 卢米拉特英国有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20080015255-A1 | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(C.N.R.S.) (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1833474-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON FLUORINATED SULPHAMIDES AND SULPHINIMIDES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067330-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON FLUORINATED SULPHAMIDES AND SULPHINIMIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015255-A1 | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides | FPR3, FPR1, AFF1 | LMNA 3682/4885MEN1 1642/4885KMT2A 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.